このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

CBT-I in Physically Active Participants With Insomnia Complaints

2026年8月31日 更新者:Giselle Soares Passos、Federal University of Jatai

Effects of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Physically Active Participants With Insomnia Complaints: a Randomized Clinical Trial

The goal of this clinical trial is to learn if Cognitive Behavioral Therapy for Insomnia (CBT-I) can treat insomnia complaints in participants physically active; men and woman; aged 30-59 years old. The main question it aims to answer is:

Can this terapy to reduce the insomnia severity? Can this terapy to improve sleep and related complaints?

Researchers will compare CBT-I vs No treatment to see if CBT-I can promote better sleep.

Participants will receive 6 weeks of treatment.

調査の概要

詳細な説明

MATERIAL AND METHODS

This is a randomized clinical trial with two parallel groups, conducted in the period from November 2025 to April 2029, in the municipality of Jataí, located in the interior of Goiás, region Midwest of Brazil. Data collection will be carried out in a private room environment, to guarantee secrecy and confidentiality of the participants' information, as well as their accommodation. All participants in the study will be identified by codes, to guarantee secrecy and confidentiality of information from participants

Sample selection Patients of the male and female gender will be selected, physically active (practice of physical exercise >150 min/week) with complaints of insomnia, who will be randomly distributed into two groups: control group (without interventions) and intervention group with CBT-I. The selected participants will be randomly distributed with an allocation rate of 1:1, according to the standards of the Consolidated of Reporting Trials (CONSORT) for Randomized Trials of Nonpharmacologic Treatments. Randomization will be carried out by an external automated online system, ensuring that the allocation is not influenced by the research team.

The selected participants will be randomly distributed (simple randomization 1:1).. The sample size was calculated considering a significance level of 5% (p=0.05), test power of 80%, difference of 4 points in the mean of the Insomnia Severity Index (ISI), and average standard deviation (sigma) of 5.0. Control group (n=25) and CBT-I Group (n=25).

The schedule of activities with the intervention and control groups will occur for a total period of up to 13 weeks. Assessments will be carried out at three different times: (1) at baseline (pre-intervention), (2) after six weeks and (3) after four weeks of follow-up.

Ethical considerations The study was approved from the Research Ethics Committee of the Federal University of Jataí (CAAE: 94602225.8.0000.0187). Participants must sign the Free and Informed Consent Form. All material from the study will be the responsibility of the researcher responsible and stored for a period of five years, then incinerated.

This research follows the ethical principles for medical research on human beings outlined in the Helsinki Declaration, contemplating the norms established by Resolution 466/2012 (1)of the National Health Council, making use of the principles of autonomy, beneficence, non-maleficence and justice. All necessary measures will be taken to guarantee the integrity, privacy and well-being of the participants during all stages of the study.

Only participants who sign the Free and Informed Consent Form will participate in the research Clarified, which must comprise the first session of the research form, whose signature for agreement will be recorded on the form itself by filling in the full name of the participant. The autonomy of the participants to answer, or not, the research will be ensured, as well as the guarantee of confidentiality and anonymity, in addition to the presentation of the risks and benefits arising from their participation. Any damage demonstrably caused by the research will be repaired in accordance with the Resolution CNS nº 466/12(1).

The consent form guarantees the right to clarify the research, withdrawal at any time from participating in the research, without any prejudice, guarantee of privacy and confidentiality, in addition to compensation for any damage resulting from the research and reimbursement of expenses arising from participation in the study.

Study design This is a randomized clinical trial with two parallel groups, conducted in the period from November 2025 to December 2028, in the municipality of Jataí, located in the interior of Goiás, Midwest region of Brazil. The protocol will be registered in the Clinicaltrials.com database.

Participants will be recruited voluntarily through advertising and leaflets in gyms in the city of Jataí-Goiás and on the official website of the Federal University of Jataí. Through contact via telephone (WhatsApp) or e-mail, the participant must fill out a registration form. Then, through a face-to-face interview, in a well-lit, air-conditioned room, free of distractions, with suitable and comfortable furniture for privacy, on the premises of Clínica Neso, located at Tiradentes N. 2567, in the city of Jataí-Goiás, volunteers will receive guidance on their search procedures and signing of the informed consent form and registration form. Volunteers interested in participating in the research will be submitted to a sequence of assessments, which aim to ensure the inclusion criteria and exclusion of this study. Included participants will be submitted to assessments on health and sleep conditions through self-applicable questionnaires and sleep assessment through actigraphy. In addition, they will also be questionnaires applied that assess frequency and duration of physical activity; chronotype of morningness and eveningness; level of cognitive and somatic alertness in pre-sleep; dysfunctional beliefs and attitudes about sleep; mood changes, depression, anxiety and stress; quality of life; sleep hygiene index; risk of obstructive sleep apnea; risk of restless legs syndrome symptoms; and body mass index.

研究の種類

介入

入学 (推定)

50

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Giselle Soares Passos, PhD
  • 電話番号:+556436068304
  • メール:passosgs@ufg.br

研究連絡先のバックアップ

研究場所

    • Goiás
      • Jatai、Goiás、ブラジル、75801-615
        • 募集
        • Tamara R. L. Zanuzzi
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Giselle S Passos, PhD
        • 副調査官:
          • Tamara Zanuzzi, MsC

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

いいえ

説明

Inclusion criteria:

  • Age range between 30-59 years;
  • Practice regular physical exercise for over 150 minutes per week;
  • Complaints of insomnia (difficulty initiating and/or maintaining sleep and/or early awakening) more than three times a week, for at least three months, associated with complaints of daytime impairments (occupational, academic or social) related to insomnia;
  • Insomnia severity index greater than fifteen (>15).

Exclusion criteria:

  • Shift workers;
  • Evidence that insomnia is associated with restless legs syndrome;
  • Evidence that insomnia is associated with medication side effects;
  • Evidence that insomnia is associated with signs or symptoms of mental disorders;
  • Abusive use of alcohol or illicit psychoactive substances.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment group (CBT-I)
This group will receive 6 weeks of CBT-I treatment
This intervention is a multicomponent therapy directed to insomnia treatment. It includes sleep restriction, cognitive therapy, stimulus control, sleep higiene, and relaxation therapy (Van Straten et la., 2018)
介入なし:Control group
This group will receive no treatment

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Insomnia severity
時間枠:(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.
The Insomnia Severity Index is a questionnaire that assesses insomnia complaints. It is a self-administered, simple and short instrument, with seven items that can be classified from 0 to 4, with the lowest final score = 0 and the highest = 28. Non-significant insomnia is considered scores from 0 to 7, lower limit for insomnia from 8 to 14, moderate insomnia from 15 to 21 and severe insomnia from 22 to 28.
(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.

二次結果の測定

結果測定
メジャーの説明
時間枠
Sleep assessment by Actigraphy
時間枠:(1) at baseline (pre-intervention), (2) six weeks and (3) four weeks of follow-up
Actigraphy is a technique that allows determining the pattern of the wake-sleep cycle, through recording motor activity, resulting from body movements. This method has been considered gold standard for assessing/investigating insomnia complaints, as it provides evidence of information such as total sleep time, total wake time, latency to sleep onset and awakenings. The Micro MotionLogger® model (Ambulatory Monitoring, Inc., USA) equipment is similar to a wristwatch, which should be used for 10 consecutive days.
(1) at baseline (pre-intervention), (2) six weeks and (3) four weeks of follow-up
Sleep quality
時間枠:(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.
Pittsburgh Sleep Quality Index (PSQI) The Pittsburg Sleep Quality Index is a questionnaire that measures the quality of sleep through seven domains that are: subjective sleep quality, sleep onset latency, duration of sleep, sleep efficiency, sleep disturbances, use of sleeping medications and daytime impairments in the last thirty days. The evaluation starts from the analysis of global scores less than or equal to 5, which suggest a good sleep quality, while scores greater than 5 suggest poor sleep quality.
(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.
Pré-sleep arousal
時間枠:(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.
Pre-Sleep Arousal Scale (PSAS) To assess the level of Pre-Sleep cognitive and somatic alertness, the questionnaire will be used self-reported Pre-Sleep Arousal Scale (PSAS), consisting of 16 items, with eight items in the assessment of cognitive alertness and eight for somatic alertness. Each item has a five-point scale that determines the intensity of the symptom experienced at the beginning of sleep, with a score of one indicating no symptom experienced and a score of five expressing an extremely intense symptom.
(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.
Subjective sleep
時間枠:(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.
Sleep Diary The sleep diary is a method used to assess the subjective perception of quality of sleep, so it must be answered in the morning upon waking. The questions contained in this questionnaire are related to sleep and wake times, the amount of hours of sleep, sleep onset latency of sleep and awakenings during the night. The sleep diary must be completed for a consecutive period of ten days.
(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.
Emotional Distress
時間枠:(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.
Depression Anxiety Stress Scale-21 (DASS-21) The DASS-21 is an instrument that assesses the intensity of symptoms of depression, anxiety, and stress. It is a self-report questionnaire with twenty-one questions. Each question has a four-point Likert scale, ranging from 0 to 3. The answers are based on how the person felt in the last seven days. The raw scores are classified into levels of normal, mild, moderate, severe, and extremely severe.
(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.
Quality of Life
時間枠:(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.
Medical Outcomes Study (SF-36) The SF-36 is a multidimensional questionnaire that covers eight components: physical functioning, role limitations due to physical health problems, role limitations due to emotional health problems, social functioning, vitality, general health perception, body pain, and mental health. All scores ranged from 0 to 100, with a higher score indicating better quality of life.
(1) at baseline (pre-intervention), (2) six weeks, and (3) four weeks of follow-up.

その他の成果指標

結果測定
メジャーの説明
時間枠
Body mass
時間枠:Baseline (pre-intervention)
Assessment of body mass index (BMI) To assess the patients' body weight, a bioimpedance scale (Multilaser - HC060N) will be used, with a capacity of up to 180kg. Height will be assessed using a digital portable stadiometer (Welmy). The body mass index will be calculated using the formula: body mass/height squared.
Baseline (pre-intervention)
Chronotype
時間枠:Baseline (pre-intervention)
Morningness-Eveningness Questionnaire - (MEQ) The Horne & Östberg Morningness-Eveningness Questionnaire (1976) is a psychometric instrument used to assess an individual's chronotype, that is, their preference natural for the times of day when they feel most alert, active and productive. It is used for classification of three main chronotypes, which are: morning, who prefers activities early in the day, wakes up and sleeps early, feels more alert in the morning; evening, who prefers activities at the end of the day, feels more willing at night, sleeps and wakes up later; and intermediate, who has no clear preference for morning or night. The score ranges from 16 to 86, in which scores between 16 and 41 determine the evening type, between 42 and 58 the indifferent type and between 59 and 86 defines the morning type (4).
Baseline (pre-intervention)
Physical activity level
時間枠:baseline (pre-intervention)
International Physical Activity Questionnaire - Short Form (IPAQ-SF) The short version of the International Physical Activity Questionnaire is used to assess the level of physical activity, based on the activities of last week. The questionnaire consists of questions about the frequency and duration of moderate, vigorous and walking physical activities. The participants will be classified as insufficiently active (<150 minutes moderate activity/week) and active (>150 minutes moderate activity)(Matsudo et al., 2001).
baseline (pre-intervention)
Restless legs syndrome symptoms
時間枠:Baseline (pre-intervention)
Restless Legs Syndrome Rating Scale (IRLS) The IRLS is a scale to assess the severity of symptoms of restless legs syndrome. Restless legs syndrome is characterized by discomfort, usually in the legs, with an urgent need to move them, in the face of unpleasant sensations, which impair significantly the sufferer's sleep. The IRLS consists of 10 questions, in which the answers have a variation from 0 (corresponds to 'none') to 5 (corresponds to 'very large'). From the sum of the points of 0-10 indicates mild severity, 11 to 20 moderate, 21 to 30 severe, 31 to 40 very severe (Masuko AH et al., 2008).
Baseline (pre-intervention)
Sleep apnea symptoms
時間枠:baseline (pre-intervention)
Stop-Bang The STOP-Bang (acronym for snoring, tiredness, observed apnea, high blood pressure, body mass index, age, neck circumference, and gender) is a self-report questionnaire that contains eight yes/no questions, used to detect obstructive sleep apnea (OSA). The scoring criteria for this questionnaire are low risk of OSA with scores of 'yes' for less than three questions and high risk for OSA with scores of 'yes' for more than three questions (Reis at al., 2015).
baseline (pre-intervention)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Giselle S Passos, PhD、Federal University of Jatai

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年7月1日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2029年12月30日

試験登録日

最初に提出

2026年5月19日

QC基準を満たした最初の提出物

2026年5月19日

最初の投稿 (実際)

2026年5月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月2日

QC基準を満たした最後の更新が送信されました

2026年8月31日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

The ethics committee guarantees the privacy of all participants.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する